Diabetes
| T2D & Obesity
Diabetes
T2D & Obesity

Oral Semaglutide for Treatment of Obesity and Type 2 Diabetes—Results from OASIS 1 and PIONEER PLUS Trial

book_2 Source: ADA 2023 - Symposium 
calendar_today Published on Medfyle: July 2023
import_contacts 7 min
headphones 5 min

In this medfyle

OASIS: in adults without type 2 diabetes with overweight or obesity, once daily oral semaglutide 50 mg led to superior and clinically meaningful decrease in body weight vs. placebo. PIONEER PLUS: in adults with inadequately controlled type 2 diabetes oral semaglutide 25 mg and 50 mg were superior to 14 mg in reducing HbA1c and body weight.

Expert commentary

Donna H. Ryan, MD

Pennington Biomedical Research Center
Baton Rouge, LA, USA

About this Medfyle
Read more arrow_downward Hide arrow_upward

This content is intended for an international audience of non-UK healthcare professionals. The content is made available through a licensing agreement between Infomedica and the American Diabetes Association (ADA).

The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content. The viewpoints expressed may not represent Infomedica, Medfyle, or the ADA.

©2023 Infomedica-Medfyle. All rights reserved.

MedfyleToday | Day 3

Feedback